deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 7-arm NCT03731260

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy

Sponsor: Blueprint Medicines Corporation

Conditions Indolent Systemic Mastocytosis
Interventions Avapritinib Placebo
Updated 21 times since 2018 Last updated: Sep 22, 2025 Started: Apr 16, 2019 Primary completion: Jun 23, 2027 Completion: Jun 23, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Indolent Systemic Mastocytosis, this trial is ongoing. The trial is conducted by Blueprint Medicines Corporation and has accumulated 21 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Mar 2022 · 4 months · monthly snapshot~Mar 2022 – ~Oct 2022 · 7 months · monthly snapshot~Oct 2022 – ~Jul 2023 · 9 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Oct 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 16 earlier versions

  1. Oct 2022 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2022 — Oct 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Nov 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  4. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  5. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  6. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  7. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  8. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  9. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  10. Mar 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  11. Aug 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  12. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  13. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  14. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2

  15. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  16. Dec 2018 — Feb 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Blueprint Medicines Corporation
Data source: Blueprint Medicines Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Ann Arbor, United States , Atlanta, United States , Barcelona, Spain , Basel, Switzerland , Berlin, Germany , Birmingham, United States , Bologna, Italy , Boston, United States , Calgary, Canada and 38 more locations